Scientists are developing all sorts of potential new treatments to tackle the most difficult cancer cases—including some that ...

A new treatment for advanced melanoma is showing promising results for people whose tumors have stopped responding to ...

New imaging tools reveal how within an hour of infection, the virus begins to alter our chromosomes to kick-start its own replication.

The combination of RPI, a genetically engineered herpes simplex virus type 1, and Opdivo shrank both injected and non-injected tumors by 30%.

University of Southern California researchers have found a way to rebrand this oft-embarrassing sore subject by genetically modifying HSV-1 and administering it to patients with treatment-resistant, ...

Malignant gliomas, which include glioblastomas, are the most frequent primary brain cancer and are associated with extremely poor prognosis. They nearly always recur after treatment, rapidly leading ...

SHELTON, CONNECTICUT / ACCESS Newswire / July 16, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) ...

The herpes simplex virus type 1 (HSV-1), which affects almost two-thirds of the world's population and is generally ...

One-in-six patients treated with the modified virus as part of a clinical trial saw their tumors disappear completely.

A cancer-killing virus could soon be approved for use after shrinking tumours in a third of people with late-stage melanoma ...

DelveInsight's, “Oncolytic Virus Cancer Therapy Pipeline Insight, 2025,” report provides comprehensive insights about 120+ ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...